(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that three Afirma-related abstracts will be presented at ENDO 2025, the annual meeting of the Endocrine Society, taking place July ...

Veracyte, Inc., a leading cancer diagnostics company, today announced that three Afirma-related abstracts will be presented at ENDO 2025, the annual meeting of the Endocrine Society, taking place ...

On a per-share basis, the South San Francisco, California-based company said it had net income of 9 cents. Earnings, adjusted for one-time gains and costs, were 31 cents per share.

Veracyte has been evaluating its ownership and operations of the company’s French subsidiary, Veracyte SAS, whose business is located in Marseille, France and includes Veracyte’s immune ...

Veracyte (NASDAQ:VCYT – Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect Veracyte to post earnings of $0.21 per ...

Veracyte has begun making the Decipher Prostate Metastatic test available to select clinical sites through an early access program and will begin taking orders for the test more broadly in June 2025.

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic Classifier for use in patients whose prostate cancer has ...

Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation ...

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release Veracyte, Inc. (Nasdaq: VCYT), a ...